Turkish Journal of Medical Sciences
Volume 50

Number 8

Article 1

1-1-2020

COVID-19 and dermatology
ÜLKER GÜL

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
GÜL, ÜLKER (2020) "COVID-19 and dermatology," Turkish Journal of Medical Sciences: Vol. 50: No. 8,
Article 1. https://doi.org/10.3906/sag-2005-182
Available at: https://journals.tubitak.gov.tr/medical/vol50/iss8/1

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Medical Sciences
http://journals.tubitak.gov.tr/medical/

Review Article

Turk J Med Sci
(2020) 50: 1751-1759
© TÜBİTAK
doi:10.3906/sag-2005-182

COVID-19 and dermatology
Ülker GÜL*
Department of Dermatology, Gülhane Faculty of Medicine, Health Sciences University, İstanbul, Turkey
Received: 14.05.2020

Accepted/Published Online: 25.06.2020

Final Version: 17.12.2020

Background/aim: Sars-CoV-2 virus infection (COVID-19) was observed in China in the last months of 2019. In the period following,
this infection spread all over the world. In March 2020 the World Health Organization announced the existence of a pandemic.
The aim of this manuscript is to investigate skin diseases associated with COVID-19 under three main headings: skin problems related
to personal protective equipment and personal hygiene measures, skin findings observed in SARS-CoV-2 virus infections, and skin
findings due to COVID-19 treatment agents.
Materials and methods: In PubMed, Google Scholar databases, skin lesions related to personal protective equipment and personal
hygiene measures, skin findings observed in SARS-CoV-2 virus infections and skin findings due to COVID-19 treatment agents subjects
are searched in detail.
Results: Pressure injury, contact dermatitis, itching, pressure urticaria, exacerbation of preexisting skin diseases, and new skin lesion
occurrence/new skin disease occurrence may be due to personal protective equipment. Skin problems related to personal hygiene
measures could include itching, dryness, and contact dermatitis. Skin findings may also be observed in SARS-CoV-2 virus infections.
The incidence of skin lesions due to COVID-19 was reported to be between 0.2% and 29%. Many skin lesions including maculopapular,
urticarial, vesicular, chilblain-like, thrombotic/ischemic, etc. are observed in COVID-19 patients. Some authors have stated that there is
an absence of SARS-CoV-2 virus infection-specific skin findings. However, in asymptomatic or presymptomatic COVID-19 patients in
particular, skin lesions can lead to the diagnosis of COVID-19. In addition, skin lesions may occur due to COVID-19 treatment agents.
Conclusion: Many skin lesions may appear as a result of COVID-19. Even in the absence of a COVID-19 diagnosis, skin findings should
be evaluated carefully in this pandemic period.
Key words: SARS-CoV-2, COVID-19, dermatology, skin findings

1. Introduction
SARS-CoV-2 virus infection (COVID-19) was observed in
China in the last months of 2019. In the period following,
this infection spread all over the world. In March 2020 the
World Health Organization announced the existence of a
pandemic [1–3].
Skin is the largest organ in our body. Factors such
as external changes, infectious agents, internal events,
and medications can cause symptoms in the skin.
This manuscript presents a review of the literature for
COVID-19 and dermatology.
2. Occupational exposure of dermatologists to SARSCoV-2 virus
Some cases of occupational exposure are symptomatic or
even serious, and some cases exhibit mild symptoms or none
at all. Therefore, especially in mild or asymptomatic cases,
skin findings may lead to the diagnosis of COVID-19 [1–7].

PCR false-negative cases were found in 33%–41% of
COVID-19 cases [6,7]. Furthermore, skin lesions may also
precede COVID-19 symptoms [8].
Dermatological examinations require the examination
of body areas such as the face, oral mucosa, etc. while
being in close contact with the patient [9,10]. For this
reason, COVID-19 diagnosed patients may be a source of
infection during the pandemic period. In addition, due to
the presence of asymptomatic cases or COVID-19 carriers,
dermatologists may also be infected. Dermatologists
should be careful when preparing for examinations and
should always wear personal protective equipment and
obey personal hygiene rules [10–14].
3. COVID-19 and skin diseases
In this manuscript, skin diseases associated with
COVID-19 are investigated under the following headings:
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3.1. Skin lesions related to personal protective equipment
(PPE) and personal hygiene (PH) measures,
3.2. Skin findings observed in SARS-CoV-2 virus
infections,
3.3. Skin findings due to COVID-19 treatment agents.
3.1. Skin lesions related to personal protective equipment
and personal hygiene measures
During the pandemic period, all people have been
practicing heightened personal hygiene (frequent
disinfectant use and washing). Healthcare workers in
particular have been exposed to the regular use of PPE
such as the N95 mask, gloves, goggles, and gowns [13–
20]. Skin problems related to PH measures and PPE were
most frequently observed in the hands (15%–85%) and
face (12%–87%). Less frequently, they were seen on the
legs, trunk, and all over the body. As the frequency of
PH application increases and PPE usage time increases
(in hours and days), the incidence of skin lesions
increases. Depending on the degree of protection and
hygiene, among health care workers 11%–89% reported
erythema, 13%–87% papule/edema, 9%–91% exudation/
crust, 12%–88% scratches, 12%–88% fissure, 30%–70%
lichenification, and 16%–84% blisters [15]. According to
one questionnaire 49.0% of health workers reported maskrelated skin reactions, and among these 41.8% had facial
skin problems and 6.2% had eye symptoms [16].
Skin lesions observed due to prolonged contact with
PPE and excessive PH are listed in Table 1 [15–30].
3.1.1. Pressure injury
The N95 masks, goggles, and face shields used as PPE
can squeeze and rub the cheeks, forehead, and nasal
bridge, which can easily cause mechanical damage to the
skin. As a result, ecchymosis, maceration, abrasion, and
erosion have been observed. The nasal bridge was the
most commonly affected area (83.1%). In addition, lesions
may occur where the stems of N95 masks create pressure,
such as the ears [10,18–20,22–25]. In one study, facial
indentation was observed in 18.8% of cases, and lesions
caused by mask stems were observed in 22.3% of cases;
8.9% (n: 36) of those affected removed their masks because

they could not tolerate them [16]. Skin indentation may
be mild or serious. Most mild skin indentations regress
spontaneously; however, if the ulceration is not properly
managed, secondary infections may occur [10].
3.1.2. Contact dermatitis (CD)
3.1.2.1. Face
CD is one of the important problems to emerge due to mask
use. Lesions often occur on the nose and cheeks [26]. Both
N95 and surgical masks contain formaldehyde and other
preservatives. For this reason, allergic contact dermatitis
(ACD) may occur. Friction, warmth, and moisture from
respiration may enhance these symptoms. Skin barrier
dysfunction and skin microbiota disorder make patients
more vulnerable to mask side effects [16,27,28].
3.1.2.2. Body
Skin dermatoses most commonly develop where gowns
adhere tightly to the skin. Friction, moisture, and warmth
in these regions may increase the risk of ACD [25].
3.1.2.3. Hands
CD has frequently been observed in the hands during the
pandemic period. Hand hygiene is extremely important.
The causes of CD in the hands are frequent contact with
disinfectants and frequent washing. After exposure to 60%–
80% alcohol, chlorine-based disinfectants, peroxyacetic
acid, and chloroform users may develop adverse
reactions (e.g., irritant CD). In addition, the frequency
and duration of skin cleaning has increased. Excessive
hygiene applications also increase CD [10,19,26]. Atopic
diathesis, low humidity, frequency of hand washing, wet
work, glove use, and duration of work are important risk
factors for the development and/or aggravation of hand
dermatitis. Hand dermatitis often appears in the form
of irritant CD. Less commonly, ACD may occur. For the
aim of CD prevention, applying hand cream frequently is
recommended [18,21,30]. Excessive washing of the skin
and repeated application of disinfectants (e.g., bleach and
alcohol) should be avoided [19].
Prolonged use of gloves also causes CD. In one study,
dry skin (73.4%), itching (56.3%), and rash (37.5%) were
reported due to the use of permanent gloves [17].

Table 1. Skin lesions related to personal protective equipment and personal hygiene measures.
Protection
type

Personal protective equipment

Personal hygiene measures

Protection
agents

N95 masks (mask and stems), N95 and surgical masks, goggles,
goggles and face shields
gowns, gloves

Disinfectants, soaps, frequent washing

Diseases

· Pressure injury
· Pressure urticaria
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· Contact dermatitis
· Itching
· Exacerbation of preexisting skin diseases
· New skin disease

· Contact dermatitis
· Itching
· Exacerbation of preexisting skin diseases
· New skin disease
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3.1.3. Itching
Itching is observed at rates between 14.8% and 55.2%
depending on the degree of protection. The incidence of
itching was 79% when protection was in use for more than
3 days. Itching was observed at the rate of 37% when using
PPE 0–4 h a day and 67% when using PPE for more than
4 h. This is especially relevant for healthcare professionals
[15]. In one study, mask-related itching was observed at
a rate of 15% [16]. In another study, facial itching was
reported at 51% due to mask use, and itching of the hands
was reported at 56.3%, due to glove use [17].
3.1.4. Pressure urticaria
Pressure urticaria is rarely observed [10,27,29].
Antihistamines such as cetirizine and loratadine
are preferred for treating pressure urticaria, and
antileukotriene agents may be added if needed [10].
3.1.5. Exacerbation of preexisting skin diseases including
seborrheic dermatitis and acne
In one study, exacerbation was reported in 43.6% (n = 44) of
acne patients, in 37.5% (n = 9) with seborrheic dermatitis,
and in all 14 acne rosacea patients [16]. Prolonged wearing
of masks and goggles may aggravate existing acne vulgaris.
Plausible mechanisms include the rupture of comedones
induced by pressure and friction, occlusion of the
pilosebaceous duct, microcirculation dysfunction due to
long-term pressure, and a humid environment which is
conducive to bacteria proliferation [10].
3.1.6. New skin lesion occurrence/new skin disease
occurrence
Frequent disinfection of the hands and the wearing of latex
gloves may result in pompholyx presenting with blisters
and itching. The long-term wearing of protective clothing
may cause sweating, which can lead to dermatitis and
folliculitis. Frequent use of shoe covers may cause fungal
infections of the feet (19). The regular use of N95 masks
has been found to cause acne (59.6%) [17,25].
3.2. Skin findings observed in SARS-CoV-2 virus
infections
The reported incidence of skin lesions was 0.2% in 1099
cases of SARS-CoV-2 infection in China [31,32]. In

another study, this rate was 4.9% (5/103) [33]. Skin rash
was reported in 29% (14/48) of patients in an Italian study
[34]. In another Italian study, cutaneous manifestations
were reported in 20.4% (18/88) of confirmed COVID-19
patients [35].
Many skin lesions are observed in COVID-19 (Table
2) [8,36,37]. The largest series (373 cases) observing skin
lesions was from Galván Casas et al. [8]. Some authors
stated that there were no SARS-CoV-2 virus infectionspecific skin findings [38]. However, some skin lesions
may help to diagnose COVID-19 [8,38].
Time to onset of skin lesions: The relationship between
skin lesions and the primary symptoms of COVID-19 has
been studied and in one study 5.9% of cases show skin
lesions before primary symptoms, 56.8% cases show lesions
with the primary findings, and 37.3% show lesions after the
primary symptoms (Table 3) [8]. In a study analyzing18
publications, in 12.5% (9/72) of the patients, skin lesions
were observed before the onset of respiratory symptoms
or COVID-19 diagnosis [39]. As a result, particularly in
asymptomatic or presymptomatic COVID-19 patients,
skin lesions can lead to a diagnosis of COVID-19 [8].
The relationship between skin lesions and disease
severity: There is no evidence that the extent of cutaneous
involvement is related to disease severity [38,39]. On the
other hand, in 2 separate reports COVID-19 and skin
lesion severity were linked in 2 patients [34,36].
Age and gender characteristics of skin lesions: In a
study reporting on 18 articles and 3 additional cases, mean
patient age was 53.6 years. In this study, males accounted
for 38.9% of cases, females accounted for 27.8% of cases,
and gender was not reported in 37.5% of cases [39].
Location of lesions: In an evaluation of publications,
the majority of lesions were localized on the trunk (66.7%,
50/72); however, 19.4% (14/72) of patients experienced
cutaneous manifestations on the hands and feet [39].
Skin lesion healing time: Generally, lesions
spontaneously healed in all patients within 10 days. The
majority of studies reported no correlation between
COVID-19 severity and skin lesions [39].

Table 2. Incidence of skin lesions in all COVID-19 cases and among all COVID-19 skin findings.
Maculapapular (%)

Urticarial (%)

Study

All COVID-19
cases

All skin
findings

All COVID-19
cases

All skin
findings

All COVID-19
cases

All skin
findings

Recalcati [35]

15.9

77.8

3.4

16.7

1.1

5.6

Hedou [33]

1.9

40

1.9

40

Galván Casas [8]
Zhang [45]
Tammaro [49]

47

Vesicular (%)

19

9

1.4
1.5
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Table 3. The relationship of skin lesions with the main symptoms of COVID-19 [8].
Lesion development
time
Before n (%)

Pseudochilblain

Vesicular

Urticarial

Livedo/
necrosis

Total

5 (7)

5(15)

3(4)

8(5)

1(5)

22 (5.9)

Synchronously n (%)

24(34)

19(56)

43(61)

108(61)

18(86)

212 (56.8)

After n (%)

42(59)

10(29)

25(35)

60(34)

2(10)

139 (37.3)

Total

71(19)

34(9.1)

71(19)

176(47.2)

Histopathologic examination: In most of the literature,
histological findings were not reported [39].
Skin findings observed in COVID-19
3.2.1. Maculopapular exanthema (MPE)
The incidence of MPE is seen in Table 2, and time of
occurrence is in Table 3 [8,33,35]. In a study analyzing
18 publications, MPE was the most common cutaneous
manifestation of COVID-19 (36.1%) [39]. Maculopapular
exanthema may also be observed during the asymptomatic
period [8]. It has also been seen in children [40].
Maculopapular exanthema accompanying COVID-19
is nonspecific (some cases have a purpuric component).
Scaling may be found, and itching is present in half of the
patients [8,37,41]. Purpura may also be present, either
punctiform or over larger areas [8,39,41,42]. Lesions may
be located in perifollicular areas. Target-like purpuric or
pseudovesicular plaques can also be seen [8,43,44]. Some
were described as similar to pityriasis rosea, erythema
elevatum diutinum, or erythema multiforme. Differential
diagnosis should be performed to account for other
infections and drug reactions [8].
3.2.2. Urticarial lesions
Urticarial lesions incidence is listed in Table 2, and time of
occurrence is in Table 3 [8,33,35,45]. In an analysis of 18
articles, urticaria was found in 9.7% of cases [39]. Urticaria
may be the first sign of COVID-19 [8,46,47]. Urticaria was
also seen during the asymptomatic phase [8,33]. It has also
been reported in children [40]. Urticaria is mainly located
on the face and upper body [33]. It is mostly distributed
on the trunk or disperse. A few cases were palmar. Itching
was very common when urticariform lesions were present
(92%) [8]. A case of cold urticaria has also been reported
in the literature [42]. Differential diagnosis should be
performed to rule out other infections and drug reactions
[8].
Zhang et al. found urticaria in 1.4% of COVID-19
patients. In this study, there were 82 nonsevere patients,
58 severe patients, and a total of 140 cases. Urticaria was
observed in 1.2% of nonsevere patients and in 1.7% of
severe patients [45].
In the literature, the histologic examination of a
female case with a urticarial lesion revealed a perivascular
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Maculopapular

21(5.6)

373

infiltrate of lymphocytes, some eosinophils, and upper
dermal edema. Oral antihistamines were added to her
treatment and she improved over a 5-day period [48].
3.2.3. Vesicular eruptions
The incidence of vesicular eruptions is seen in Table
2, and the time of occurrence is in Table 3 [8,35,49].
Vesicular eruptions have also been observed during
the asymptomatic phase [8]. In one study analyzing 18
publications, papulovesicular rash was found in 34.7% of
cases [39].
Some lesions were on the trunk and consisted of small
monomorphic vesicles that were chickenpox-like. Lesions
appeared in middle aged patients. Itching was common
(68%) [8]. Two out of 130 patients had isolated herpetiform
lesions appear on their trunks during their inpatient stay
[49]. In the lesions, vesicles surrounded by erythematous
halos were observed [49].
3.2.4. Acral lesions
Acral lesions in COVID-19 are mentioned in different
publications under different names [8,37,50–56]. Galván
Casas et al. have divided acral lesions into 2 groups as
follows [8]:
3.2.4.a. Chilblains-like lesions (perniosis-like lesions and
pseudo-chilblain)
The cutaneous manifestations consisted of erythematoviolaceous papules and macules, with possible vesicles,
bullous, or pustules on the acral area [8,32,53,54]. These
lesions resembled chilblains and had purpuric areas,
affecting the hands and feet [8,53]. They were usually
asymmetrical [8]. In an analysis of 18 publications,
chilblains-like lesions were found in 19% of cases [39].
They occurred before the main symptoms in 7% of the
cases. (Table 3) [8]. In another study, lesions were found
in 25.4% of asymptomatic patients [55]. Chilblains-like
lesions appeared more commonly after the onset of the
disease and were not associated with severe disease [8].
The appearance time of the lesions was 10 days after the
onset of the disease [55]. They may cause pain (32%) or
itching (30%). Chilblains-like lesions affected children and
teenage patients at a higher rate [8,51,53,55]. Chilblains
in youth are a potential sign of COVID-19 infection
[52]. No significant difference in gender was noticed
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[55]. No association with cold exposure, comorbidities,
or drug intake was recorded [53]. In 63 cases, a history
of autoimmune disorders was found in only 6 patients
(one with ANA positivity), while familial or personal
history of coagulation defects was seen in 4 cases [55].
In another study, antinuclear antibody, C3 and C4,
anticardiolipin antibodies, and cryoglobulin were negative
[54]. In contrast, Andina et al. found that coagulation
tests and lupus anticoagulant levels were normal in all
patients tested. These lesions were observed in mildly
symptomatic COVID-19 patients. In addition, chilblainslike lesions had an excellent prognosis, usually requiring
no therapy [51]. In another publication, the appearance
of chilblains associated with Raynaud’s phenomenon
was reported in one case [42]. Histology of the lesions
showed a mild superficial +/– deep perivascular dermatitis
[53]. The following histological findings were found in
a 23-year-old male COVID-19 patient with chilblains
lesions; no intraluminal fibrin thrombi were identified,
no fibrin was identified within venule walls, and direct
immunofluorescence results were negative [56].
3.2.4.b. Acral ischemia (livedo or necrosis) (6%)
When evaluated according to the onset of the main
symptoms, acral ischemia developed prior to onset in 5%
of the cases, synchronously in 86% of the cases, and later
in 10% of cases (Table 3). These patients showed different
degrees of lesions suggesting occlusive vascular disease
including areas of acral ischemia. Livedoid/necrotic lesions
appeared in older patients with more severe disease (10%
mortality) [8]. In one study analyzing 18 publications,
painful purple papules in the acral area were found in 19%
of cases, and livedo reticularis was found in 2.8% of cases
[39]. In one study, 7 patients were reported to have acroischemia findings including finger/toe cyanosis, skin bulla,
and dry gangrene. D-dimer, fibrinogen, and fibrinogen
degradation product (FDP) were significantly elevated
in most patients. Prothrombin time was prolonged in 4
patients. D-dimer and FDP levels increased progressively
when exacerbated by COVID-2019, and 4 patients were
diagnosed with definite disseminated intravascular
coagulation [57]. Thrombosis-related livedoid lesion
and bulla may develop in patients [58]. Zhang et al.
reported three cases of thrombosis associated with
antiphospholipid antibodies [59]. Another study found
abnormal coagulation parameters were associated with
poor prognosis in patients [60].
3.2.5. Other lesions observed in COVID-19
· Erythema multiforme-like lesions (EMLL): EMLL
was observed in 4 female patients hospitalized due to
COVID-19; the mean age of patients was 66.75 years
(range 58–77). The mean time period between the
onset of COVID-19 symptoms and the appearance of
cutaneous lesions was 19.5 days (range 16–24). Typical

target lesions were observed in two patients. Lesions
were on the back and then spread to the face and limbs
within 1 week, without involvement of palms or soles. All
patients were treated with systemic corticosteroids and
had progressive resolution of the skin lesions within 2–3
weeks. Histopathological examination showed nonspecific
findings. Three patients had their oral cavity examined,
which revealed palatal macules and petechiae [61]. It was
reported that a female COVID-19 patient had generalized
exanthematous pustulosis with erythema multiforme-like
lesions [62]. In another paper it was found that atypical
erythema multiforme palmar plaques lesions were formed
due to Sars-Cov-2 [63].
· Vasculitis [64]
· Transient livedo reticularis [65]
· Nonpruritic annular fixed plaques: In a 39-year-old
male with a fever of 39 °C, nonpruritic annular fixed
plaques were observed. This rash was located on the upper
limbs, chest, neck, abdomen, and palms, sparing the
face and mucous membranes. Blood count, electrolytes,
C-reactive protein, and anti-DNA antibodies were at
normal levels. Histological findings were unspecific but
consistent with viral exanthemata [66].
· Acute hemorrhagic edema [43,44]
· Dengue fever-like [40,44]
· Venous thromboembolism: The incidence of venous
thromboembolism was 25% (20/81) in severe novel
coronavirus pneumonia patients [67].
· An increased number of herpes zoster and superficial
fungal infection cases were observed in COVID-19
patients [8].
· Oral herpes simplex virus type 1 reactivation was seen
in an intubated patient in intensive care [33].
3.2.6. Oral mucosa lesions
In three cases (two suspected and one confirmed), painful
ulcers and blisters in the oral cavity (desquamative
gingivitis) were observed [68]. Galván Casas et al. also
reported enanthem in COVID-19 cases [8,68].
3.3. Skin findings due to COVID-19 treatment agents
The treatment agents for COVID-19 can also cause
skin lesions. In cases of COVID-19 with skin lesions,
drug eruptions should be considered in the differential
diagnosis. Below are the cutaneous side effects of the
treatment agents used in COVID-19.
3.3.1. Hydroxychloroquine (HCQ)
Hydroxychloroquine is an antimalarial agent which also
has antiinflammatory and immunomodulatory activities.
Hydroxychloroquine is used for short term COVID-19
treatment. However, some people use HCQ for longterm treatment without a doctor’s recommendation due
to COVID-19 phobia. For these reasons, all patients
having skin lesions should be questioned about their use
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of HCQ during the pandemic period. HCQ may cause
adverse cutaneous drug eruptions (ACDRs). In 6 of 180
patients diagnosed with cutaneous lupus erythematosus
and dermatomyositis ACDRs have been observed.
ACDRs occurred 5 to 14 days after initiation of HCQ
treatment and none were life threatening. Eruptions were
characterized as lichenoid, urticarial, or exanthematous
and resolved after discontinuation of HCQ treatment
[69]. In one case, generalized pustular figurate erythema
was seen [70]. One of the important side effects of HCQ
is hydroxychloroquine-induced pruritus [71]. Moreover,
it may cause acute generalized exanthematous pustulosis,
urticaria, mucocutaneous dyspigmentation, Stevens–
Johnson‐like eruptions, alopecia, the bleaching of hair,
and psoriasis flare-ups [72].
3.3.2. Azithromycin
Azithromycin is widely used and is generally considered
a safe medicine. Azithromycin rarely causes skin
reactions such as Bullous fixed drug eruption, Stevens–
Johnson syndrome, DRESS, leukocytoclastic vasculitis,
hypersensitivity syndrome, etc. [73–77].
3.3.3. Favipiravir
Favipiravir is a nucleoside analog that is well-known as a
broad-spectrum antiviral drug. In the commercial drug
prospectus, skin rash (< 1%) and eczema (<0.5%) pruritus
are reported. In COVID-19 treatment with favipiravir,
cutaneous adverse effects have not been observed [78].
3.3.4. Remdesevir
Remdesivir is a monophosphoramidate prodrug of an
adenosine analog. Some adverse skin effects have been
reported including itching and swelling (especially of
the face, tongue, and throat). In one study, Wang et al.

found skin rash in 7% of the remdesevir group and 3% of
a placebo group of COVID-19 patients. Remdesevir was
discontinued due to cutaneous adverse effects in 2 cases
(1%) [79]. In another study, skin rash was observed in a
total of 4 cases [3 cases (9%) in invasive ventilation and 1
case (5%) in noninvasive oxygen support] [80].
3.3.5. Oseltamivir
Oseltamivir has been approved for influenza treatments
and may cause cutaneous side effects such as angioedema,
Stevens–Johnson syndrome, toxic epidermal necrolysis,
etc., however this is rare [81–85].
3.3.6. Combination of lopinavir/ritonavir
Lopinavir/ritonavir is an HIV-1 protease inhibitor.
Cutaneous adverse effects are given below [86–88].
· Common: maculopapular rash, eczema, seborrheic
dermatitis, night sweats, and pruritus,
· Uncommon: alopecia, capillaritis, and vasculitis,
· Rare: Steven–Johnson syndrome, erythema multiforme,
and acute generalized exanthematous pustulosis.
4. Conclusion
Many skin lesions may appear during the COVID-19
pandemic period: skin lesions related to personal protective
equipment and personal hygiene measures, skin findings
observed in SARS-CoV-2 virus infections, and cutaneous
drug eruption due to COVID-19 treatment agents. Even
in the absence of a COVID-19 diagnosis, skin findings
should be evaluated carefully in this pandemic period. In
asymptomatic or presymptomatic COVID-19 patients,
skin lesions can lead to the diagnosis of COVID-19.
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